MedTrace Logo

Eggs and Age-related Macular Degeneration (EggsAMD) Study.

NCT07021027 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-05-28

No results posted yet for this study

Summary

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this research is to determine descriptive statistics, change over time and estimate effect sizes for retinal sensitivity, and vision, cognition and physical function. By completing these research objectives, the researchers hope to gain preliminary evidence in support of a larger trial that will assess the impact of egg consumption on eye health in adults with AMD.

Conditions

  • Intermediate Age-Related Macular Degeneration

Interventions

DRUG

Whole Egg - 4

Participants will be asked to consume 4 medium Eggland's Best eggs per day for 5 months.

DRUG

Whole Egg - 2

Participants will be asked to consume 2 medium Eggland's Best eggs per day for 5 months.

Sponsors & Collaborators

  • Kathryn Starr

    lead OTHER

Principal Investigators

  • Kathryn N Starr, PhD, RDN · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-18
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021027 on ClinicalTrials.gov